John C. Thomas Sells 6,168 Shares of NantKwest Inc. (NK) Stock
NantKwest Inc. (NASDAQ:NK) Director John C. Thomas sold 6,168 shares of the stock in a transaction on Friday, November 25th. The stock was sold at an average price of $7.50, for a total value of $46,260.00. Following the sale, the director now directly owns 309,621 shares of the company’s stock, valued at $2,322,157.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
NantKwest Inc. (NASDAQ:NK) opened at 6.54 on Thursday. NantKwest Inc. has a 1-year low of $5.43 and a 1-year high of $18.74. The stock’s 50 day moving average price is $6.84 and its 200 day moving average price is $7.14. The firm’s market cap is $538.73 million.
Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of NantKwest by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 152,196 shares of the company’s stock worth $1,251,000 after buying an additional 3,309 shares during the period. Bank of New York Mellon Corp increased its stake in shares of NantKwest by 39.4% in the second quarter. Bank of New York Mellon Corp now owns 78,443 shares of the company’s stock worth $487,000 after buying an additional 22,155 shares during the period. California State Teachers Retirement System increased its stake in shares of NantKwest by 144.2% in the second quarter. California State Teachers Retirement System now owns 34,954 shares of the company’s stock worth $217,000 after buying an additional 20,643 shares during the period. Swiss National Bank increased its stake in shares of NantKwest by 16.8% in the second quarter. Swiss National Bank now owns 42,450 shares of the company’s stock worth $264,000 after buying an additional 6,100 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new stake in shares of NantKwest during the second quarter worth $228,000. Institutional investors and hedge funds own 24.23% of the company’s stock.
Several equities research analysts recently weighed in on NK shares. Canaccord Genuity reaffirmed a “buy” rating and set a $18.00 price target on shares of NantKwest in a report on Friday, August 19th. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a report on Saturday, November 19th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $23.00 target price (down previously from $32.00) on shares of NantKwest in a report on Wednesday, August 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $17.70.
NantKwest, Inc, formerly Conkwest, Inc, is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.